Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KMPH

Zevra Therapeutics (KMPH) Stock Price, News & Analysis

Zevra Therapeutics logo

About Zevra Therapeutics Stock (NASDAQ:KMPH)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$4.48
$6.27
52-Week Range
N/A
Volume
64,100 shs
Average Volume
189,500 shs
Market Capitalization
$200.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive KMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KMPH Stock News Headlines

“All the land that you see I will give to you and your offspring forever…”
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
Zevra Therapeutics closes sale of Rare Disease PRV for $150M
Zevra Therapeutics price target raised to $25 from $23 at Canaccord
Zevra Therapeutics price target raised to $22 from $20 at Guggenheim
Zevra Therapeutics reports Q4 EPS (67c), consensus (40c)
See More Headlines

KMPH Stock Analysis - Frequently Asked Questions

Zevra Therapeutics, Inc. (NASDAQ:KMPH) announced its quarterly earnings results on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). Zevra Therapeutics had a negative trailing twelve-month return on equity of 16.12% and a negative net margin of 328.56%.

Zevra Therapeutics (KMPH) raised $60 million in an initial public offering on Thursday, April 16th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zevra Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Meta Platforms (META), SCYNEXIS (SCYX), BioCryst Pharmaceuticals (BCRX), Zoom Communications (ZM) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
3/30/2022
Today
7/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KMPH
CIK
1434647
Employees
22
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.56 million
Net Margins
-328.56%
Pretax Margin
-335.26%
Return on Equity
-16.12%
Return on Assets
-14.17%

Debt

Debt-to-Equity Ratio
0.14
Current Ratio
10.10
Quick Ratio
10.10

Sales & Book Value

Annual Sales
$10.72 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
23.28
Book Value
$3.63 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
34,505,000
Free Float
34,125,000
Market Cap
$200.47 million
Optionable
Optionable
Beta
2.16

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:KMPH) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners